Beryl Drugs Ltd (BERLDRG) — shareholding pattern, promoter holding, financials and share price
About Beryl Drugs Ltd (BERLDRG)
Beryl Drugs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BERLDRG and on the BSE under scrip code 524606. Its ISIN is INE415H01017.
Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing [1]
Beryl Drugs Limited, based in Indore, India, is involved in the manufacture, sale, and export of branded and generic pharmaceutical formulations both locally and internationally.
The company specializes in the manufacture of I.V. fluids, injectables, eye/ear drops, and veterinary products, reflecting a broad portfolio in its offering.
Listed peers in Pharmaceuticals: Dipna Pharmachem Ltd, Starsource Multitrade Ltd, Ortin Global Ltd, Saroja Pharma Industries India Ltd, Unjha Formulations Ltd, Colinz Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹24.37 a share on 10 Jul 2026, Beryl Drugs Ltd (BERLDRG) was valued at a price-to-earnings ratio of 29.44x against an industry P/E of 36.41x and a price-to-book of 1.3x on a book value of ₹18.74 per share as of Mar 2025. Solomo computes return on equity of 4.42% and return on capital employed of 6.85% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 29.44x
- Industry P/E
- 36.41x
- P/B
- 1.3x
- EPS (TTM)
- ₹0.83
- Book value / share
- ₹18.74
- ROE
- 4.42%
- ROCE
- 6.85%
- ROA
- 2.63%
- Debt / equity
- 0.43x
- Dividend yield
- 0%
- EBITDA margin
- 12.86%
- 52-week range
- ₹15.92 – ₹30
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Beryl Drugs Ltd (BERLDRG) reported revenue of ₹19.31 crore, net profit of ₹0.42 crore and earnings per share of ₹0.83. That compares with revenue of ₹21.15 crore and net profit of ₹0.58 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹5.47 crore and net profit ₹0.56 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 14.48 | 26.84 | 26.73 | 21.15 | 19.31 |
| Net profit (₹ cr) | -0.66 | 0.77 | 0.77 | 0.58 | 0.42 |
| EPS (₹) | -1.3 | 1.52 | 1.52 | 1.14 | 0.83 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.13% | 10.54% | 13.13% | -20.88% |
| Profit growth | 14.84% | 64.58% | - | -24.68% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 27.82% of Beryl Drugs Ltd (BERLDRG) (up 0.34 pp QoQ). Market capitalisation was ₹12 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: PRADEEP KUMAR JAIN 3.52%, MAYANK SIYAL 2.07%, SAMIR NARENDRA GUPTA 1.77%, JINESH JOSEPH 1.67%, PUNJABHAI KESHAVBHAI JADEJA 1.23%, RAM BABU VIJAY 1.19%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 27.82% | - | - | - | 72.18% |
| Mar 2026 | 27.48% | - | - | - | 72.52% |
| Dec 2025 | 26.38% | - | - | - | 73.62% |
| Sep 2025 | 26.38% | - | - | - | 73.62% |
| Jun 2025 | 26.38% | - | - | - | 73.62% |
| Mar 2025 | 26.38% | - | - | - | 73.62% |
| Dec 2024 | 26.38% | - | - | - | 73.62% |
| Sep 2024 | 26.38% | - | - | - | 73.62% |